Pembrolizumab plus chemotherapy extends survival in triple-negative breast cancer
16480
post-template-default,single,single-post,postid-16480,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Pembrolizumab plus chemotherapy extends survival in triple-negative breast cancer

Home > Blogs  > Pembrolizumab plus chemotherapy extends survival in triple-negative breast cancer

08 Aug Pembrolizumab plus chemotherapy extends survival in triple-negative breast cancer

Posted at 11:37h in Blogs by

In patients with previously untreated locally advanced or metastatic TNBC, the addition of pembrolizumab to chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine–carboplatin) resulted in significantly longer overall survival than chemotherapy alone in the CPS-10 subgroup (PD-L1 expression scores of ≥ 10). No new safety signals emerged. (Ref: Cortes J et al. N Engl J Med. July 21, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6962392637601402880

 

No Comments

Sorry, the comment form is closed at this time.